James Chih‐Hsin Yang
0000-0002-5586-5138
Publication & Citation Trends
Publications
0 total
Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation
Cited by 2
Semantic Scholar
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Cited by 2,645
Semantic Scholar
Abstract 4752: Exon-16-skipping HER2 contributes to osimertinib-resistance through Src-independent manner inEGFRL858R/T790M-positive non-small-cell lung cancer
Cited by 1
Semantic Scholar
Factors to Influence Autonomous Decision Making by Patients in Cancer Clinical Trials
Cited by 0
Semantic Scholar
Abstract A080: A phase 1 study of single-agent pexidartinib in Asian patients with advanced solid tumors (NCT02734433)
Cited by 1
Semantic Scholar
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways OA
Cited by 14
Semantic Scholar
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial OA
Cited by 133
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(880)
Lung Cancer Research Studies
(301)
Colorectal Cancer Treatments and Studies
(283)
Lung Cancer Diagnosis and Treatment
(225)
Cancer Immunotherapy and Biomarkers
(127)
Affiliations
AstraZeneca (United Kingdom)
Zhejiang International Studies University
Philadelphia College of Osteopathic Medicine
Zhejiang Chinese Medical University
Hebron University